Trial Profile
Phase II trial of AGS 16C3F in patients with renal cell carcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2015
Price :
$35
*
At a glance
- Drugs AGS 16C3F (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Jul 2015 New trial record
- 02 Jun 2015 This phase II study is planned with AGS-16C3F at 1.8 mg/kg, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.